Delivers up-to-date industry news on topics like drug approvals, product recalls, company expansions and acquisitions, market trends for all OSD forms, as well as excipients, packaging and supply chain issues. Monitors market trends in specific drug categories as well as in supplements/nutraceuticals. Provides updates on clinical trials. Includes alerts about new or upcoming regulatory issues.
The drugmaker says it filed for U.S. approval of semaglutide 25 mg for overweight and obesity earlier this year.
read more
The agency placed a hold on a phase 1b study of Vyne’s BET inhibitor following an observation of testicular toxicity in dogs from a non-clinical study.
read more
The deal will help Merck KGaA to sharpen its focus on rare tumors, as well as strengthen its presence in the U.S.
read more
Pfizer has expanded its “cost realignment program” to save an additional $1.2 billion, adding an R&D reorganization to the plan.
read more
Sanofi announced the closing of the sale of a 50% controlling stake of Opella to U.S. private equity firm Clayton, Dubilier & Rice.
read more
The acquisition expands France-based Roquette’s U.S. footprint and adds to the company’s formulation capabilities and drug delivery research and development.
read more
The new site will support clinical packaging for oral solid dose and capsule-based dry powder inhaler drugs.
read more
If approved, Wegovy would become the first oral formulation of a GLP-1 indicated for chronic weight management.
read more
The drugmaker plans to eliminate 516 positions at its facilities in Lawrenceville, New Jersey, as part of a broad restructuring plan.
read more
The makers of Nature Made vitamins announced the grand opening of a new manufacturing and research & development facility in New Albany, Ohio.
read more
Madrigal, looking to expand Rezdiffra into patient populations with compensated MASH cirrhosis, has now announced two-year biomarker results from this group.
read more
The FDA’s Office of Prescription Drug Promotion has flagged promotional communications from Mayne regarding its Nextstellis combined hormonal contraceptives.
read more
UnitedHealth Group CEO Andrew Witty has stepped down as CEO and the company, citing “personal reasons.”
read more
Barentz has entered exclusive discussions to acquire 100% equity of Fengli Group, a specialty chemicals distributor for pharma excipients and APIs in China.
read more
The once-daily pill is a first-in-class combination of aroxybutynin and atomoxetine.
read more